Celltrion Healthcare’s stock price is plummeting.
As of 11 am on the 14th, Celltrion Healthcare is trading at 74,400 won, down 7.81% from the previous day.
Currently, it is tentatively counted as foreigners net selling 3491 shares of Celltrion Healthcare and institutions net selling 24,000 shares. In the past five days, individual investors net sold 64,786 shares, while foreigners and institutional investors net bought 548,066 shares and 111,902 shares, respectively.
Celltrion Healthcare is the exclusive distributor of Celltrion’s biosimilars. Celltrion continued its upward trend by announcing the decision to buy back shares of Celltrion and Celltrion Healthcare on the 10th.
Then, on the 14th, when allegations of accounting fraud (accounting fraud) such as inflating inventory assets surfaced again, it turned to a downtrend. The Financial Supervisory Service has submitted an opinion to the Securities and Futures Commission that Celltrion executives and others should be reported to the prosecution. Discussions are expected to begin next week.
This article was jointly written by Electronic Newspaper and Thinkpool, a financial AI specialist. This is an ‘AI Humanoid Article’ with the reporter’s coverage added to the AI-based data.
Reporter Seo Hee-won, Electronic Newspaper Internet (shw@etnews.com)
.
